newsfilter
← Latest News
GlobeNewswire·

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray Phase 3 registrational trial of etripamil for atrial